It can, therefore, be proposed that the widely used for B-cell lymphoma treatment BTK inhibitors, apart from other well-studies pathways [247], exert their action via their contribution to the inhibition of the NLRP3 inflammasome activation. Here, BTK is linked to B-cell non-Hodgkin lymphoma.